The Efficacy & Safety of the UAS Immunotherapy Protocol

The Efficacy and Safety of the United Allergy Service (UAS) Immunotherapy Protocol

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01699659

Enrollment

Registered

2012-10-04

Start date

2012-04-30

Completion date

2012-09-30

Last updated

2012-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perennial Allergic Rhinitis With Seasonal Variation

Keywords

Allergic Rhinitis, Allergen Immunotherapy

Brief summary

Hypothesis: The UAS Immunotherapy protocol is efficacious and at least as efficacious as protocols described in the Allergy literature.

Detailed description

Patients will be assessed for efficacy of the immunotherapy protocol by completing Consented-IRB approved clinical, medication, quality of life survey questions comparing current status while on therapy in contrast to 12 months before the inception of therapy.

Interventions

OTHERallergen immunotherapy

allergy shots

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Allergic rhinitis between 18 and 65 years old who have chosen to undergo immunotherapy.

Exclusion criteria

* No beta blocker use, * no pregnancy, * no systemic steroids, * no severe asthma/copd, * no severe collagen vascular disorders, * no neoplastic or uncontrolled seizure activity, * no previous anaphylaxis, no significant cardiovsacular disease.

Design outcomes

Primary

Measure	Time frame	Description
change in symptom scores from 12 months before therapy initiation in contrast to determination during 1 to 2 years of therapy (retrospective).	Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy.	Enrolled patients completed surveys pertinent to symptom scores, contrasting current status on immunotherapy compared (by recall) to a 12 month time point prior to initiation of therapy.

Secondary

Measure	Time frame	Description
Changes in medication plus symptom aggregate score.	Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy.	Aggregate Medication and Symptom surveys were compared to determine changes from a 12 month time point prior to inception of therapy to current time point of 1 to 2 years of therapy.

Other

Measure	Time frame	Description
Quality of Life (QOL) scores	Assessment contrasts current status (at 1 to 2 years of therapy) to a point 12 months prior to the onset of therapy	QOL scores will be calculated after one to 2 years of therapy and contrasted with QOL reflecting status 12 months prior to initiation of therapy.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026